Sevuparin sodium is under clinical development by Modus Therapeutics and currently in Phase I for Malaria. According to GlobalData, Phase I drugs for Malaria have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sevuparin sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sevuparin sodium overview
Sevuparin sodium (DF-02) is under development for the treatment of malaria, sepsis and septic shock. It is administered as an intravenous infusion and subcutaneous injection. The drug candidate is a polysaccharide drug derived from heparin, a low anticoagulant heparin (LAH) derivative. It was also under development for the treatment of malaria and acute vaso-occlusive crisis (VOC) associated with sickle cell disease (SCD).
Modus Therapeutics overview
Modus Therapeutics, a subsidiary of Modus Therapeutics Holding AB, is a biotechnology company focused on the development of new drug for the treatment of sickle cell disease (SCD). The company’s lead product candidate sevuparin is an innovative, proprietary polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects that restores blood flow and prevent further microvascular obstruction in SCD patients. It also develops sevuparin for the management of acute vaso-occlusive crises (VOCs) and treatment of severe malaria. The company markets its drugs in Sweden and abroad. Modus Therapeutics is headquartered in Stockholm, Sweden.
For a complete picture of Sevuparin sodium’s drug-specific PTSR and LoA scores, buy the report here.